Michelle LaSpaluto - Chimerix Chief Officer
| CMRX Stock | USD 8.50 0.03 0.35% |
Executive
Michelle LaSpaluto is Chief Officer of Chimerix
| Age | 50 |
| Address | 2505 Meridian Parkway, Durham, NC, United States, 27713 |
| Phone | 919 806 1074 |
| Web | https://www.chimerix.com |
Latest Insider Transactions
Michelle LaSpaluto Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michelle LaSpaluto against Chimerix stock is an integral part of due diligence when investing in Chimerix. Michelle LaSpaluto insider activity provides valuable insight into whether Chimerix is net buyers or sellers over its current business cycle. Note, Chimerix insiders must abide by specific rules, including filing SEC forms every time they buy or sell Chimerix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michelle LaSpaluto over a month ago Disposition of 2260 shares by Michelle LaSpaluto of Chimerix at 4.5113 subject to Rule 16b-3 | ||
Michelle LaSpaluto over six months ago Disposition of 64275 shares by Michelle LaSpaluto of Chimerix at 1.97 subject to Rule 16b-3 |
Chimerix Management Efficiency
The company has return on total asset (ROA) of (0.3364) % which means that it has lost $0.3364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5617) %, meaning that it created substantial loss on money invested by shareholders. Chimerix's management efficiency ratios could be used to measure how well Chimerix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.64 in 2025. Return On Capital Employed is likely to drop to -0.83 in 2025. At this time, Chimerix's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 110.1 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 9.6 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robert Arbeit | X4 Pharmaceuticals | 77 | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Robert MBBS | Instil Bio | N/A | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Sourav Kundu | NextCure | 64 | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Kevin Shaw | NextCure | 50 | |
| Suba Krishnan | Mereo BioPharma Group | 60 | |
| Stacy Rollinger | NextCure | N/A | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Adam JD | Day One Biopharmaceuticals | 58 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Andrew Gengos | Terns Pharmaceuticals | 61 | |
| James Kanter | Terns Pharmaceuticals | N/A | |
| Thomas Rollins | Assembly Biosciences | 69 | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
Management Performance
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.34 |
Chimerix Leadership Team
Elected by the shareholders, the Chimerix's board of directors comprises two types of representatives: Chimerix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chimerix. The board's role is to monitor Chimerix's management team and ensure that shareholders' interests are well served. Chimerix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chimerix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Michael MBA, President CEO | ||
| David CPA, Exec Officer | ||
| Joshua Allen, Chief Imipridones | ||
| Dr MBA, Chief Officer | ||
| Michael Alrutz, interim CEO, Senior Vice President General Counsel | ||
| Pablo MD, Head Affairs | ||
| Roy Ware, Chief Manufacturing and Technology Officer | ||
| Thomas Riga, Chief Officer | ||
| Dr JD, General VP | ||
| Randall Lanier, Chief Science Officer | ||
| Michelle LaSpaluto, Chief Officer |
Chimerix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chimerix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (430.74) % | ||||
| Current Valuation | 660.18 M | ||||
| Shares Outstanding | 93.05 M | ||||
| Shares Owned By Insiders | 6.74 % | ||||
| Shares Owned By Institutions | 52.90 % | ||||
| Number Of Shares Shorted | 4.14 M | ||||
| Price To Earning | (3.43) X | ||||
| Price To Book | 6.50 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Chimerix Stock Analysis
When running Chimerix's price analysis, check to measure Chimerix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chimerix is operating at the current time. Most of Chimerix's value examination focuses on studying past and present price action to predict the probability of Chimerix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chimerix's price. Additionally, you may evaluate how the addition of Chimerix to your portfolios can decrease your overall portfolio volatility.